Vir chief Scangos picks Herbert ‘Skip’ Virgin to run R&D; Ardelyx forges $160M deal with Kyowa Hakko Kirin
→ A month ago George Scangos blazed through a biotech buyout, two billion-dollar drug development deals and more than $500 million in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
